Everything below concerns albumin binding. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-21. Numbers and descriptions here follow the published literature rather than marketing material.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
=== Absorption === 2,6-DCBQ is mainly absorbed via the oral route, typically through the ingestion of contaminated drinking water. Dermal absorption is also considered a viable pathway following aqueous exposure. The compound's low molecular weight and moderate lipophilicity favor absorption across the gastrointestinal tract. However, the high reactivity may limit total systemic bioavailability. The quinone structure reacts rapidly with biological nucleophiles in physiological fluids, leading to localized interactions before the unchanged compound can reach systemic circulation.
In May 2025, Moore signed into law a bill that would establish a $25 million grant fund to expand abortion access for uninsured or underinsured individuals, funded a $1 surcharge on insurance plans sold under the Affordable Care Act. The law made Maryland become the first state to use these funds for this purpose. The program was blocked from going into effect by federal health officials in January 2026, who said the program "exceeds permissible use" of the fees collected by the Affordable Care Act. In May 2026, Moore signed into law a bill requiring hospitals to perform abortions in emergency medical situations.
Maggot therapy improves healing in chronic ulcers. In diabetic foot ulcers there is tentative evidence of benefit. A Cochrane review of methods for the debridement of venous leg ulcers found maggot therapy to be broadly as effective as most other methods, but the study also noted that the quality of data was poor. In 2003, the United States Food and Drug Administration (FDA) cleared maggots from the common green bottle fly for use as a "medical device" in the US for the purpose of treatment of:
Sources: en.wikipedia.org
"David J. Gross, a celebrated U.S. theoretical physicist, calls himself an optimist—especially concerning the future of his field. He's certain that somewhere out there lurks a final, unified theory of nature, just waiting to be discovered. But ... he estimates it's more likely that we'll destroy ourselves in nuclear warfare first. And [as a Nobel laureate in physics and] as the latest recipient of a $3-million Special Breakthrough Prize in Fundamental Physics, he's using the opportunity to warn the world of this dire peril. [p. 90.] [Says Gross:] 'I'd estimate that the annual chance for nuclear war is now 2 percent.'" (p. 93.) Jerry Brown, 'I Taste Ashes in the Wind' (review of Serhii Plokhy, The Nuclear Age: An Epic Race for Arms, Power, and Survival, Norton, 422 pp.; David Holloway, Nuclear Weapons: An International History, Yale University Press, 708 pp.; Daniel Ellsberg, edited by Michael Ellsberg and Jan R. Thomas, Truth and Consequence: Reflections on Catastrophe, Civil Resistance, and Hope, Bloomsbury, 363 pp.), The New York Review of Books, vol. LXIX, no. 15 (8 October 2026), pp. 18, 20–21. Reviewer Jerry Brown writes: "Congress is now considering Trump's Golden Dome, a trillion-dollar scheme to place an ineffective missile defense 'shield' over the entire [United States]. ... Our leaders are complacent or distracted with respect to the risks of nuclear horror. They are men driven by grievance and whim. The public is uninformed or else desensitized. ...
=== Mechanism of action === Calcitonin gene-related peptide (CGRP) has been shown to be involved in the development of migraine by widening blood vessels in the brain. Galcanezumab is a monoclonal antibody which attaches to and blocks CGRP, thereby helping blood vessels to return to their normal size.
Granin (chromogranin and secretogranin) is a protein family of regulated secretory proteins ubiquitously found in the cores of amine and peptide hormone and neurotransmitter dense-core secretory vesicles.
Patrice Motsepe, businessman Herman Mashaba, businessman, president of ActionSA Mogoeng Mogoeng, former chief justice of South Africa Mamokgethi Phakeng, former vice chancellor of the University of Cape Town Tshepo Motsepe, businesswoman and first lady of South Africa Baaitse Nkabinde, former judge at the South African high court Refiloe Phoolo, musician and businessman Thato Sikwane, disk jockey and music producer Connie Ferguson, actress, film producer and businesswoman Motsi Mabuse, dancer and judge on Strictly Come Dancing
Sources: en.wikipedia.org
The ionization efficiency of DESI is complex and depends on several parameters such as, surface effects, electrospray parameters, chemical parameters and geometric parameters. Surface effects include chemical composition, temperature and electric potential applied. Electrospray parameters include electrospray voltage, gas and liquid flow rates. Chemical parameters refers to the sprayed solvent composition, e.g. addition of NaCl. Geometric parameters are α, β, d1 and d2 (see figure on the right). Furthermore, α and d1 affect the ionization efficiency, while β and d2 affect the collection efficiency. Results of a test performed on a variety of molecules to determine optimal α and d1 values show that there are two sets of molecules: high molecular weight (proteins, peptides, oligosaccharide etc.) and low molecular weight (diazo dye, stereoids, caffeine, nitroaromatics etc.). The optimal conditions for the high molecular weight group are high incident angles (70–90°) and short d1 distances (1–3 mm). The optimal conditions for the low molecular weight group are the opposite, low incident angles (35–50°) and long d1 distances (7–10 mm). These test results indicate that each group of molecules has a different ionization mechanism; described in detail in the Principle of operation section. The sprayer tip and the surface holder are both attached to a 3D moving stage which allow to select specific values for the four geometric parameters: α, β, d1 and d2.
=== Isoleucine === In plants and microorganisms, isoleucine is biosynthesized from pyruvic acid and alpha-ketoglutarate. Enzymes involved in this biosynthesis include acetolactate synthase (also known as acetohydroxy acid synthase), acetohydroxy acid isomeroreductase, dihydroxyacid dehydratase, and valine aminotransferase. In terms of regulation, the enzymes threonine deaminase, dihydroxy acid dehydrase, and transaminase are controlled by end-product regulation. i.e. the presence of isoleucine will downregulate threonine biosynthesis. High concentrations of isoleucine also result in the downregulation of aspartate's conversion into the aspartyl-phosphate intermediate, hence halting further biosynthesis of lysine, methionine, threonine, and isoleucine.
At one point, Israeli commandos boarded helicopters prepared to fly into Iraq, but the mission was called off after a phone call from US defense secretary Dick Cheney, reporting on the extent of coalition efforts to destroy Scuds and emphasizing that Israeli intervention could endanger US forces. In addition to the attacks on Israel, 47 Scud missiles were fired into Saudi Arabia, and one missile was fired at Bahrain and another at Qatar. The missiles were fired at both military and civilian targets. One Saudi civilian was killed, and 78 others were injured. No casualties were reported in Bahrain or Qatar. The Saudi government issued all its citizens and expatriates with gas masks in the event of Iraq using missiles with warheads containing chemical weapons. The government broadcast alerts and 'all clear' messages over television to warn citizens during Scud attacks. On 25 February 1991, a Scud missile hit a US Army barracks of the 14th Quartermaster Detachment, out of Greensburg, Pennsylvania, stationed in Dhahran, Saudi Arabia, killing 28 soldiers and injuring over 100. A subsequent investigation found that the assigned Patriot missile battery had failed to engage due to the loss of significance effect in the onboard computer's floating point calculations compounding over 100 hours of consecutive use, shifting the range gate position far enough to lose contact with the Scud during tracking action.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.